

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number
WO 2005/004911 A3

(51) International Patent Classification⁷: A61K 39/39,
39/04, A61P 31/06

(21) International Application Number:
PCT/DK2004/000488

(22) International Filing Date: 7 July 2004 (07.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2003 01046 9 July 2003 (09.07.2003) DK
PA 2003 01403 27 September 2003 (27.09.2003) DK

(71) Applicant (for all designated States except US):
STATENS SERUM INSTITUT [DK/DK]; Artillerivej 5,
DK-2300 Copenhagen S (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): AGGER, Else,
Marie [DK/DK]; Krudtmøllegårds Allé 9, DK-2300
Copenhagen S (DK). ANDERSEN, Peter [DK/DK];
Sparreholmvej 47, DK-2700 Brønshøj (DK). OLSEN,
Anja [DK/DK]; Jacob Bulls Allé 121, DK-2860 Søborg
(DK). ROSENKRANDS, Ida [DK/DK]; Kastaniehaven
9, DK-3500 Værløse (DK).

(74) Common Representative: TOFT, Lars; Statens Serum
Institut, Corporate Affairs, Artillerivej 5, DK-2300 Copen-
hagen S (DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
17 February 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COM-
POSITIONS AND VACCINES

(57) Abstract: The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecyl-
lammonium-bromide/chloride (DDA) and a lipid extract from The present invention provides a vaccine adjuvant consisting of a com-
bination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from <The present invention
provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA)
and a lipid extract from *Mycobacterium bovis*. The present invention provides a vaccine adjuvant consisting of a combination of a
surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from *Mycobacterium bovis* <The present
invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chlo-
ride (DDA) and a lipid extract from *Mycobacterium bovis* BCG The present invention provides a vaccine adjuvant consisting of a
combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from *Mycobacterium*
bovis BCG<The present invention provides a vaccin adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecy-
lammonium-bromide/chloride (DDA) and a lipid extract from *Mycobacterium bovis* BCG. The present invention provides a vaccine
adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract
from <i>*Mycobacterium bovis* BCG<i>. <The present invention provides a vaccine adjuvant consisting of a combination of a sur-
factant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from <i>*Mycobacterium bovis* BCG<i>.
The total lipid extract contains both apolar lipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were
found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved
in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a
mammal in order to combat pathogens, or as a treatment for cancer.

WO 2005/004911 A3